Drug Interference in Clinical Chemistry: Studies on Ascorbic Acid

Siest, Gérard; Appel, William F.; Blijenberg, G B; Capolaghi, B.; Galteau, Marie‐Madeleine; Heusghem, C; Hjelm, Markus; Lauer, K L; Perron, B Le; Loppinet, V.; Love, C.C.; Royer, R; Tognoni, C; Wilding, Peter

doi:10.1515/cclm.1978.16.2.103

Cited by 16 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A variação pré-analítica é o erro de resultado da sumarização de todos os limites de variação, desde a coleta da amostra, transporte e preservação antes da introdução do sistema analítico. Este é especialmente importante, podendo levar a variações instrumentais, que são erros durante o método de análise, podendo estes, serem controlados e documentados (SIEST et al, 1988).…”

Section: Interferências Analíticasunclassified

“…Também são inclusos os fatores genéticos como a raça, além dos fatores externos, como o tabagismo, nutrição e condições sociais (SIEST et al, 1988).…”

Section: Interferências Analíticasunclassified

“…Na prática clínica, estas interferências são pouco conhecidas e não se dispõe de informação em numerosas situações (SIEST et al, 1988;PORTOS, 1992;PEDRAZZI, 1997), Este falso resultado provocado pela interação dos medicamentos com as análises laboratoriais poderá trazer consequências inesperadas, tanto na interpretação do diagnóstico pelo médico, como comprometendo a saúde do paciente, podendo levá-lo ao óbito. Nestas situações onde ocorre a interferência de medicamentos, diversos mecanismos desencadeantes podem operar ocasionalmente ou de forma simultânea (PORTOS, 1992).…”

Section: Interferências Analíticasunclassified

See 2 more Smart Citations

Estudo de revisão sobre a interferência de hipoglicemiantes orais no exame químico de urina

Ramos

Vieira

Mascarenhas

et al. 2015

RBM

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a disease that has been increasing exponentially in the last years of individuals'life and an option for pharmacological treatment is through oral hypoglycemic agents (OH). Because they are widely used drugs being the urinary the major route of excretion, this treatment can cause variations in the results of urinary parameters. Therefore, this study aims at evaluating the interference caused by the use of hypoglycemic agents in urinalysis. With this aim a bibliographic search was conducted in different databases, selecting relevant scientific articles on the topic: diabetes, laboratory interference and pharmacological treatment. The OH can be classified into three groups according to the mechanism of action: stimulators of insulin by the pancreas, such as sulfonylureas and metiglinidas; insulin sensitizers, such as biguanides, thiazolidinediones and the ones reducing the absorption of carbohydrates, which are the inhibitors of alpha-glucosidase. Urinalysis is a complementary tool in the management of MD due to its low cost and easy collection. The classes of oral hypoglycemic agents identified as potentially interfering in urinalysis were biguanides (metformin) and sulfonylureas (tobultamida, tolazamide, gliclazide, clorpropramida). They interfere on the parameters of density, protein, glucose, ketones, bilirubin, leading to an inappropriate diagnosis and an unsatisfactory treatment, generating an injury to the welfare of the patient.

show abstract

Section: Interferências Analíticasunclassified

“…Também são inclusos os fatores genéticos como a raça, além dos fatores externos, como o tabagismo, nutrição e condições sociais (SIEST et al, 1988).…”

Section: Interferências Analíticasunclassified

See 1 more Smart Citation

Estudo de revisão sobre a interferência de hipoglicemiantes orais no exame químico de urina

Ramos

Vieira

Mascarenhas

et al. 2015

RBM

View full text Add to dashboard Cite

show abstract

“…In 1978 an expert group was convened within the European Community to study drug interferences and establish recommendations. 1 In 1984 the French Society of Clinical Chemistry and the International Federation of Clinical Chemistry also addressed this issue and published, in French and in English, recommendations for the evaluation of drug interferences. 2,3 The National Committee for Laboratory Standards published proposed guidelines for interference testing in 1986.…”

Section: Introductionmentioning

confidence: 99%

Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies

Sonntag¹,

Scholer²

2001

Ann Clin Biochem

View full text Add to dashboard Cite

SUMMARY.A group of international experts prepared two lists of drugs with their serum/plasma and urine concentrations, which should be used when evaluating the performance of a new laboratory method. The two lists were veri®ed by running in vitro interference studies in three European laboratories on Hitachi instruments. The study identi®ed the following new interferants: acid phosphatase in serum by ibuprofen and theophylline; non-prostatic acid phosphatase in serum by cefoxitin and doxycycline; creatine kinase MB in serum by doxycycline; total bilirubin in serum (Jendrassik±Grof method) by rifampicin and intralipid; total bilirubin in serum (DPD method) by intralipid; creatinine in serum (Jaffe method) by cefoxitin; fructosamine in serum by levodopa and methyldopa; uric acid in serum by levodopa, methyldopa and tetracycline; carbamazepine in serum by doxycycline, levodopa, methyldopa and metronidazole; digitoxin in serum by rifampcin; phenytoin in serum by doxycycline, ibuprofen, metronidazole and theophylline; theophylline in serum by acetaminophen, cefoxitin, doxycycline, levodopa, phenylbutazone and rifampicin; tobramycin in serum by cefoxitin, doxycycline, levodopa, rifampicin and phenylbutazone; valproic acid in serum by phenylbutazone; C3 in serum by intralipid; C4 in serum by doxycycline; rheumatoid factor in serum by ibuprofen and metronidazole; pancreatic amylase and total amylase in urine by acetylcysteine, ascorbic acid, cefoxitin, gentamicin, levodopa, methyldopa and o¯oxacin; magnesium in urine by acetylcysteine, gentamicin and methyldopa; b 2 -microglobulin in urine by ascorbic acid; total protein in urine by ascorbic acid, Ca-dobesilate and phenylbutazone.Interference in acid phosphatase, creatine kinase MB and bilirubin methods was observed at very low analyte concentrations, and therefore it may not be evident at higher concentrations. The study con®rmed the usefulness of the recommendation.

show abstract

“…Their blood glucose levels were determined 8-12 h after the last vitamin C intake using three 'specific' enzymatic assays: glucose dehydrogenase [5), hexokinase [6] and glucose oxidase [7]. In normal subjects, blood glucose determinations using hexokinase and glucose oxidase, respectively, yield identical results when inter fering substances are excluded [2,8,9], The oxidizable substance, vitamin C, interferes with the latter enzymatic reaction during the second step of the determination process [1], No such interference is noted with the glucose dehydrogenase and the hexokinase assay systems, which are direct measurement methods. The results of the present study arc shown in table I.…”

mentioning

confidence: 99%

Letter to the Editor

1981

Nephron

View full text Add to dashboard Cite

Drug Interference in Clinical Chemistry: Studies on Ascorbic Acid

Cited by 16 publications

References 10 publications

Estudo de revisão sobre a interferência de hipoglicemiantes orais no exame químico de urina

Estudo de revisão sobre a interferência de hipoglicemiantes orais no exame químico de urina

Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies

Letter to the Editor

Contact Info

Product

Resources

About